Clinical trials: COPD Chronic Obstructive Pulmonary Disease
- Condition COPD Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Chronic Obstructive Pulmonary Disease COPD
Realize the Current Situation of COPD Patients in China
This is a multi-centre, prospective, observational study to realize the current situation of COPD patients in China. About 5000 COPD patients will be enrolled from 50 participating sites around China and followed up for one year.
- Trial name
- REAL (NCT03131362)
- Where
- China
- Volunteers
- 5,020 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238197
- Testing
- Atrovent® Inhalation Solution
- Volunteers
- 477 people
- Sponsor
- Boehringer Ingelheim
Asthma, Chronic Obstructive Pulmonary Disease
Interpreting Respiratory Oscillometry in Adult Asthma and COPD: a Delphi Study
This is an international Delphi study to consolidate expert consensus on the use of respiratory oscillometry in the management of adult patients with asthma or chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT06313372
- Testing
- Respiratory oscillometry
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Scius Healthcare Solutions Pty Ltd
Asthma, Chronic Obstructive Pulmonary Disease
A Study of Patients With Chronic Disease
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF
- Trial name
- NCT04263727
- Where
- 5 sites in United States
- Volunteers
- 579 people
- Sponsor
- Target PharmaSolutions, Inc.
Pulmonary Disease, Chronic Obstructive
Comparative Effectiveness of COPD Treatments
To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the combination of a long-acting bronchodilators (LABA and the long-acting muscarinic antagonists (LAMA) tiotropium…
- Trial name
- NCT03376295
- Testing
- LABA and the LAMA tiotropium (LABA-TIO), LABA and an ICS (LABA-ICS)
- Where
- Canada
- Volunteers
- 3,954 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary…
- Trial name
- BEACON (NCT01529632)
- Testing
- QVA149, NVA237, QAB149
- Where
- 26 sites in Austria, Denmark and 3 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Obstructive Pulmonary Disease
Study in Patients With COPD
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug
- Trial name
- NCT00215423
- Testing
- Formoterol Fumarate
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dey
COPD, Interstitial Lung Disease
Autologous Stem Cell Treatment for Chronic Lung Disease Study
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day.
- Trial name
- NCT03044431
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Lung Institute
Chronic Obstructive Airway Disease
Clinical Study to Investigate Safety and Performance of NeuRx DPS in Patients Undergoing Bilateral Lung Transplantation
This study is a prospective, single-center feasibility study to acquire more knowledge regarding the NeuRx DPS and develop a routine in the optimal pacing of the diaphragm with this system during the weaning period from…
- Trial name
- NCT02411383
- Testing
- NeuRx Diaphragm Pacing System
- Where
- Belgium
- Volunteers
- 4 people
- Sponsor
- Synapse Biomedical
COPD
Impact of Ibis on Patients With Advanced COPD
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.
- Trial name
- NCT03131622
- Testing
- Digital Therapeutics
- Volunteers
- 240 people
- Sponsor
- Senscio Systems
Pulmonary Disease, Chronic Obstructive
Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease
To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings
- Trial name
- COPD (NCT02177318)
- Testing
- Spiriva (tiotropium bromide) inhalation capsules
- Where
- 418 sites in Japan
- Volunteers
- 3,588 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Small Cell Lung Cancer
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
- Trial name
- NCT05337163
- Testing
- Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination
- Where
- China
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Pulmonary Disease, Chronic Obstructive
The Study for Evaluating Factors Relating to Daily Step Counts and Physical Activity in Japanese Patients With COPD.
This study is conducted as a multicenter, non-interventional, cross-sectional study. Patients will be enrolled in the study by a continuous registration method after patients provide written informed consent.
- Trial name
- STEP-COPD (NCT03642613)
- Where
- Japan
- Volunteers
- 505 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Exacerbations Among Patients Receiving Breztri (EROS Study)
EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Retrospective Studies
- Trial name
- NCT06514144
- Testing
- BGF
- Where
- United States
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Asthma, COPD
A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
This was an open-label, multiple-dose, study of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 micrograms (mcg) twice daily (BID) (2 puffs of MF/F MDI 50/5 mcg, administered twice a day…
- Trial name
- NCT00604500
- Testing
- SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
- Volunteers
- 272 people
- Sponsor
- Organon and Co
Comparative Effectiveness Study
Treatment and Exacerbation in COPD Subjects
This is a study comparing the effects of ICS containing treatments in patients with chronic obstructive pulmonary disease (COPD) in a real world setting, using the UK Clinical Practice Research Datalink (CPRD) linked with…
- Trial name
- NCT03375450
- Testing
- Standard of Care
- Where
- United Kingdom
- Volunteers
- 60,243 people
- Sponsor
- AstraZeneca
Asthma, COPD
An Open Study to Assess the Robustness of the CRC749 Inhaler
To confirm the robustness of the CRC749 inhaler.
- Trial name
- NCT02474017
- Testing
- MGR001, CRC749 inhaler
- Where
- 2 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Mylan Pharma UK Ltd.
Pulmonary Disease, Chronic Obstructive
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
- Trial name
- NCT03979807
- Testing
- Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol
- Where
- United States
- Volunteers
- 11,296 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Medlink for Diagnosing of Diabetes Mellitus, COPD, CHF, Myasthenia Gravis and Hypertension
MEDLINK IS A POCKET-SIZED MEDLINK is a pocket-sized, verbally interactive, programmable medical device that allows physicians to select which medical measurements they would like to take for a specific patient.
- Conditions
- Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Myasthenia Gravis
- Trial name
- Medlink (NCT06256172)
- Testing
- Medlink
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Olawuyi Racett Nigeria Ltd